Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Masonic Cancer Center, University of Minnesota
• Collaborator: Pfizer

Criteria

Inclusion Criteria:

• Adequate performance status:

• Breast - Karnofsky score > 50;

• Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score ≤2

• If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation.

• Normal organ function within 14 days of study entry

• Diagnosis of one of the following malignancies:

• Metastatic breast cancer (BR)

• Metastatic ovarian cancer (OV)

• Metastatic endometrial cancer (EM)

• Metastatic cervical cancer (CX)

Breast Cancer Inclusion Criteria:

• Measurable metastatic disease (>1cm) in at least one site other than bone-only

• Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease

• Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen.

Ovarian Cancer Inclusion Criteria:

• Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)

• Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma).

• Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens.

Endometrial Cancer Inclusion Criteria:

• Measurable metastatic disease

• Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens

Cervical Cancer Inclusion Criteria:

• Measurable metastatic disease

• Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens.

Exclusion Criteria:

• Had/have the following prior/concurrent therapy:

• Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed)

• Investigational drugs/agents within 14 days of first dose of 852A

• Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)

• Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions

• Radiotherapy within 3 weeks of the first dose of 852A

• Hematopoietic cell transplantation within 4 weeks of first dose of 852A

• Evidence of active infection within 3 days of first dose of 852A

• Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable)

• Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication

• History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk

• Uncontrolled intercurrent or chronic illness

• Active autoimmune disease requiring immunosuppressive therapy within 30 days

• Active coagulation disorder not controlled with medication

• Pregnant or lactating

• Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated

• Any history of brain metastases or any other active central nervous system (CNS) disease